A viral ubiquitin ligase has substrate preferential sumo targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence

PLoS Pathogens

Volumn 7, Issue 9, 2011, Pages

  Boutell, Chris ^a   Cuchet Lourenço, Delphine ^a   Vanni, Emilia ^a   Orr, Anne ^a   Glass, Mandy ^a   McFarlane, Steven ^a   Everett, Roger D ^a  

^a MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; PROTEIN; SP100 PROTEIN; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE ICP0; UNCLASSIFIED DRUG; VIRUS ENZYME; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; IMMEDIATE EARLY PROTEIN; ISOPROTEIN; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; REPRESSOR PROTEIN; SIM1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; VIRUS PROTEIN; VMW110 PROTEIN, HUMAN HERPESVIRUS 1;

ANTIVIRAL ACTIVITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FETUS; GENE MUTATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; NONHUMAN; ORTHOLOGY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UBIQUITINATION; VIRUS INHIBITION; VIRUS REACTIVATION; CELL CULTURE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PROTEIN DOMAIN;

HUMAN HERPESVIRUS 1;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELLS, CULTURED; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; REPRESSOR PROTEINS; SUBSTRATE SPECIFICITY; SUMO-1 PROTEIN; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; VIRAL PROTEINS;

EID: 80053459914     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002245     Document Type: Article

References (74)

1. Randow F, Lehner PJ, (2009) Viral avoidance and exploitation of the ubiquitin system. Nat Cell Biol 11: 527-534.
2. Everett RD, (2006b) The roles of ICP0 during HSV-1 infection. Alpha herpesviruses: molecular and cellular biology In: Sandri-Goldin RM, editors. Wymondham, United Kingdom Caister Academic Press pp. 39-64.
3. Boutell C, Sadis S, Everett RD, (2002) Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J Virol 76: 841-850.
4. Lium EK, Silverstein S, (1997) Mutational analysis of the herpes simplex virus type 1 ICP0 C3HC4 zinc ring finger reveals a requirement for ICP0 in the expression of the essential alpha27 gene. J Virol 71: 8602-8614.
5. Everett RD, (1987) A detailed mutational analysis of Vmw110, a trans-acting transcriptional activator encoded by herpes simplex virus type 1. Embo J 6: 2069-2076.
6. Everett R, O'Hare P, O'Rourke D, Barlow P, Orr A, (1995) Point mutations in the herpes simplex virus type 1 Vmw110 RING finger helix affect activation of gene expression, viral growth, and interaction with PML-containing nuclear structures. J Virol 69: 7339-7344.
7. O'Rourke D, Elliott G, Papworth M, Everett R, O'Hare P, (1998) Examination of determinants for intranuclear localization and transactivation within the RING finger of herpes simplex virus type 1 IE110k protein. J Gen Virol 79 (Pt 3): 537-548.
8. Everett RD, Parsy ML, Orr A, (2009) Analysis of the functions of herpes simplex virus type 1 regulatory protein ICP0 that are critical for lytic infection and derepression of quiescent viral genomes. J Virol 83: 4963-4977.
9. Everett RD, Freemont P, Saitoh H, Dasso M, Orr A, et al. (1998) The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J Virol 72: 6581-6591.
10. Chelbi-Alix MK, de The H, (1999) Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18: 935-941.
11. Muller S, Dejean A, (1999) Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J Virol 73: 5137-5143.
12. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, et al. (2006) PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 80: 7995-8005.
13. Everett RD, Parada C, Gripon P, Sirma H, Orr A, (2008) Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J Virol 82: 2661-2672.
14. Everett RD, Chelbi-Alix MK, (2007) PML and PML nuclear bodies: Implications in antiviral defence. Biochimie 89: 819-830.
15. Everett RD, Murray J, (2005) ND10 Components Relocate to Sites Associated with Herpes Simplex Virus Type 1 Nucleoprotein Complexes during Virus Infection. J Virol 79: 5078-5089.
16. Everett RD, Murray J, Orr A, Preston CM, (2007) Herpes Simplex Virus Type 1 Genomes Are Associated with ND10 Nuclear Substructures in Quiescently Infected Human Fibroblasts. J Virol 81: 10991-11004.
17. Cuchet-Lourenço D, Boutell C, Lukashchuk V, Grant K, Sykes A, et al. (2011) SUMO pathway dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog, 7: e1002123.
18. Xie Y, Kerscher O, Kroetz MB, McConchie HF, Sung P, et al. (2007) The yeast Hex3.Slx8 heterodimer is a ubiquitin ligase stimulated by substrate sumoylation. J Biol Chem 282: 34176-34184.
19. Uzunova K, Gottsche K, Miteva M, Weisshaar SR, Glanemann C, et al. (2007) Ubiquitin-dependent proteolytic control of SUMO conjugates. J Biol Chem 282: 34167-34175.
20. Prudden J, Pebernard S, Raffa G, Slavin DA, Perry JJ, et al. (2007) SUMO-targeted ubiquitin ligases in genome stability. Embo J 26: 4089-4101.
21. Sun H, Leverson JD, Hunter T, (2007) Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. Embo J 26: 4102-4112.
22. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, et al. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10: 538-546.
23. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, et al. (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10: 547-555.
24. Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y, (2004) Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci U S A 101: 14373-14378.
25. Song J, Zhang Z, Hu W, Chen Y, (2005) Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J Biol Chem 280: 40122-40129.
26. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I, (2006) Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem 281: 16117-16127.
27. Stehmeier P, Muller S, (2009) Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell 33: 400-409.
28. Kerscher O, (2007) SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep 8: 550-555.
29. Weisshaar SR, Keusekotten K, Krause A, Horst C, Springer HM, et al. (2008) Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBS Lett 582: 3174-3178.
30. Geoffroy MC, Jaffray EG, Walker KJ, Hay RT, (2010) Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell 21: 4227-4239.
31. Lukashchuk V, Everett RD, (2010) Regulation of ICP0-null mutant herpes simplex virus type 1 infection by ND10 components ATRX and hDaxx. J Virol 84: 4026-4040.
32. Hayashi T, Seki M, Maeda D, Wang W, Kawabe Y, et al. (2002) Ubc9 is essential for viability of higher eukaryotic cells. Exp Cell Res 280: 212-221.
33. Dasso M, (2008) Emerging roles of the SUMO pathway in mitosis. Cell Div 3: 5.
34. Zhang XD, Goeres J, Zhang H, Yen TJ, Porter AC, et al. (2008) SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol Cell 29: 729-741.
35. Bailey D, O'Hare P, (2002) Herpes simplex virus 1 ICP0 co-localizes with a SUMO-specific protease. J Gen Virol 83: 2951-2964.
36. Boyer-Guittaut M, Birsoy K, Potel C, Elliott G, Jaffray E, et al. (2005) SUMO-1 modification of human transcription factor (TF) IID complex subunits: inhibition of TFIID promoter-binding activity through SUMO-1 modification of hsTAF5. J Biol Chem 280: 9937-9945.
37. Mullen JR, Brill SJ, (2008) Activation of the Slx5-Slx8 ubiquitin ligase by poly-small ubiquitin-like modifier conjugates. J Biol Chem 283: 19912-19921.
38. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, et al. (2006) Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 24: 341-354.
39. Berndt A, Hofmann-Winkler H, Tavalai N, Hahn G, Stamminger T, (2009) Importance of covalent and noncovalent SUMO interactions with the major human cytomegalovirus transactivator IE2p86 for viral infection. J Virol 83: 12881-12894.
40. Boutell C, Everett R, Hilliard J, Schaffer P, Orr A, et al. (2008) Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner. J Virol 82: 10647-10656.
41. Davido DJ, von Zagorski WF, Lane WS, Schaffer PA, (2005) Phosphorylation site mutations affect herpes simplex virus type 1 ICP0 function. J Virol 79: 1232-1243.
42. Everett RD, Meredith M, Orr A, Cross A, Kathoria M, et al. (1997) A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. Embo J 16: 1519-1530.
43. Lilley CE, Chaurushiya MS, Boutell C, Landry S, Suh J, et al. (2010) A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses. EMBO J 29: 943-955.
44. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP, (2006) The mechanisms of PML-nuclear body formation. Mol Cell 24: 331-339.
45. Jensen K, Shiels C, Freemont PS, (2001) PML protein isoforms and the RBCC/TRIM motif. Oncogene 20: 7223-7233.
46. Cuchet D, Sykes A, Nicolas A, Orr A, Murray J, et al. (2011) PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication. J Cell Sci 124: 280-291.
47. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, et al. (1998) Identification of three major sentrinization sites in PML. J Biol Chem 273: 26675-26682.
48. Everett RD, Boutell C, McNair C, Grant L, Orr A, (2010) Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins. J Virol 84: 3476-3487.
49. Wang L, Oliver S, Sommer M, Rajamani J, Reichelt M, et al. (2011) Disruption of PML Nuclear Bodies is Mediated by ORF61 SUMO-interacting Motifs and Required for Varicella-Zoster Virus Pathogenesis in Skin. PLoS Pathog 7 In Press.
50. Ulrich HD, (2008) The fast-growing business of SUMO chains. Mol Cell 32: 301-305.
51. Bieniasz PD, (2004) Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 5: 1109-1115.
52. Tavalai N, Stamminger T, (2010) Intrinsic cellular defense mechanisms targeting human cytomegalovirus. Virus Res 157: 128-133.
53. Hay RT, (2005) SUMO: a history of modification. Mol Cell 18: 1-12.
54. Seeler JS, Marchio A, Losson R, Desterro JM, Hay RT, et al. (2001) Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification. Mol Cell Biol 21: 3314-3324.
55. Gu H, Roizman B, (2009) The two functions of herpes simplex virus 1 ICP0, inhibition of silencing by the CoREST/REST/HDAC complex and degradation of PML, are executed in tandem. J Virol 83: 181-187.
56. Meredith M, Orr A, Elliott M, Everett R, (1995) Separation of sequence requirements for HSV-1 Vmw110 multimerisation and interaction with a 135-kDa cellular protein. Virology 209: 174-187.
57. Boutell C, Canning M, Orr A, Everett RD, (2005) Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7. J Virol 79: 12342-12354.
58. Boutell C, Everett RD, (2003) The Herpes Simplex Virus Type 1 (HSV-1) Regulatory Protein ICP0 Interacts with and Ubiquitinates p53. J Biol Chem 278: 36596-36602.
59. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S, (2003) Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 115: 565-576.
60. Hay RT, (2004) Modifying NEMO. Nat Cell Biol 6: 89-91.
61. Morris JR, Boutell C, Keppler M, Densham R, Weekes D, et al. (2009) The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 462: 886-890.
62. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, et al. (2009) Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462: 935-939.
63. Boggio R, Colombo R, Hay RT, Draetta GF, Chiocca S, (2004) A mechanism for inhibiting the SUMO pathway. Mol Cell 16: 549-561.
64. Ribet D, Hamon M, Gouin E, Nahori MA, Impens F, et al. (2010) Listeria monocytogenes impairs SUMOylation for efficient infection. Nature 464: 1192-1195.
65. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, et al. (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99: 15655-15660.
66. Stow ND, Stow EC, (1986) Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110. J Gen Virol 67: 2571-2585.
67. Everett RD, (1989) Construction and characterization of herpes simplex virus type 1 mutants with defined lesions in immediate early gene 1. J Gen Virol 70: 1185-1202.
68. Everett RD, Boutell C, Orr A, (2004) Phenotype of a herpes simplex virus type 1 mutant that fails to express immediate-early regulatory protein ICP0. J Virol 78: 1763-1774.
69. Everett RD, Cross A, Orr A, (1993) A truncated form of herpes simplex virus type 1 immediate-early protein Vmw110 is expressed in a cell type dependent manner. Virology 197: 751-756.
70. Schenk P, Ludwig H, (1988) The 65 K DNA binding protein appears early in HSV-1 replication. Arch Virol 102: 119-123.
71. Showalter SD, Zweig M, Hampar B, (1981) Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4. Infect Immun 34: 684-692.
72. Stuurman N, de Graaf A, Floore A, Josso A, Humbel B, et al. (1992) A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J Cell Sci 101: 773-784.
73. Sternsdorf T, Jensen K, Will H, (1997) Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol 139: 1621-1634.
74. Hofmann H, Sindre H, Stamminger T, (2002) Functional interaction between the pp71 protein of human cytomegalovirus and the PML-interacting protein human Daxx. J Virol 76: 5769-5783.